Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No EU Fast Track for AZ’s Imfinzi In Stage III Lung Cancer

Executive Summary

AstraZeneca will be disappointed at the European Medicines Agency’s refusal of its request for accelerated assessment of Imfinzi in earlier-stage lung cancer as the company is aiming to take hold of this new indication and run with it.


Related Content

US Filing For AZ’s Imfinzi In Stage III Lung Cancer
Half Of All EU Fast-Track Requests Fail; AZ’s Imfinzi Among Latest


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts